GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Rekah Pharmaceutical Industry REKA.TA · ILA

Health Care · Tel Aviv · 🇮🇱 Israel

Compare

1,030.00

+0.19%

Close of 9 Nov 2026, in ILA

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in ILS, from our data supplier.

FY2024

Revenue

ILS 321.7m

FY2015FY2024

Net income

ILS 6.2m

FY2015FY2024

Free cash flow

ILS 17.8m

FY2015FY2024

Shareholders' equity

ILS 161.9m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
RevenueILS 321.7mILS 321.7mILS 292.4mILS 263.9mILS 265.5mILS 196.5mILS 198.6mILS 200.8mILS 218.4mILS 209.9m
Gross profitILS 71.9mILS 80.2mILS 78.7mILS 65.2mILS 68.6mILS 61.1mILS 64.2mILS 66.3mILS 67.8mILS 66.6m
Research and developmentILS 4.1mILS 3.8mILS 3.2mILS 2.1mILS 1.5mILS 1.7mILS 2.6mILS 2.5mILS 1.9mILS 1.4m
Operating income−ILS 7.3mILS 2.9mILS 13.3mILS 14.1mILS 20.9mILS 11.5mILS 16.0mILS 13.2mILS 7.2mILS 7.3m
Net incomeILS 6.2m−ILS 6.9m−ILS 2.0mILS 6.6mILS 10.8mILS 4.0mILS 7.0m−ILS 25.1m−ILS 11.0mILS 2.7m
Diluted earnings per share0.54-0.61-0.180.580.950.340.64-2.61-1.150.32

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assetsILS 447.2mILS 484.7mILS 448.4mILS 437.1mILS 419.7mILS 367.1mILS 300.3mILS 295.0mILS 322.7mILS 323.8m
Cash and short-term investmentsILS 7.1mILS 19.3mILS 20.3mILS 18.6mILS 36.9mILS 25.6mILS 31.7mILS 25.0mILS 33.4mILS 20.3m
Total liabilitiesILS 285.3mILS 329.2mILS 286.4mILS 264.1mILS 254.2mILS 212.0mILS 148.9mILS 149.9mILS 217.2mILS 200.9m
DebtILS 134.2mILS 183.7mILS 154.4mILS 165.8mILS 166.3mILS 144.3mILS 84.3mILS 80.0mILS 95.1mILS 91.1m
Shareholders' equityILS 161.9mILS 155.5mILS 162.0mILS 173.0mILS 165.5mILS 155.2mILS 151.4mILS 145.0mILS 105.5mILS 123.0m
Shares outstanding11m11m11m11m11m11m11m10m10m8m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operationsILS 26.5mILS 28.4mILS 39.0mILS 21.2mILS 11.3mILS 33.9mILS 17.3mILS 24.5mILS 22.1mILS 5.8m
Capital spending−ILS 8.7m−ILS 11.8m−ILS 13.5m−ILS 14.0m−ILS 18.8m−ILS 45.4m−ILS 15.2m−ILS 16.5m−ILS 13.4m−ILS 13.1m
Free cash flowILS 17.8mILS 16.5mILS 25.5mILS 7.2m−ILS 7.6m−ILS 11.5mILS 2.1mILS 8.0mILS 8.7m−ILS 7.3m
Dividends paid——−ILS 10.0m———————

Latest quarters

By quarter end

Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
RevenueILS 75.1mILS 72.9mILS 76.1mILS 76.2mILS 87.2mILS 68.7mILS 89.7mILS 86.0m
Gross profitILS 17.0mILS 16.6mILS 19.7mILS 19.4mILS 16.0mILS 13.6mILS 22.9mILS 20.2m
Operating income−ILS 2.6m−ILS 1.9mILS 194,000ILS 184,000−ILS 4.2mILS 17.6mILS 2.8m−ILS 19,000
Net income−ILS 5.3m−ILS 4.1m−ILS 2.4m−ILS 2.3m−ILS 4.7mILS 12.0mILS 1.2m−ILS 901,000
Diluted earnings per share-0.48-0.36-0.21-0.19-0.391.050.11-0.08
Total assetsILS 414.7mILS 422.4mILS 436.6mILS 447.2mILS 454.4mILS 451.8mILS 482.9mILS 484.7m
Cash and short-term investmentsILS 6.1mILS 3.0mILS 7.8mILS 7.1mILS 3.7mILS 5.4mILS 11.1mILS 19.3m
DebtILS 128.2mILS 127.2mILS 121.0mILS 126.9mILS 133.5mILS 124.1mILS 166.2mILS 176.8m
Shareholders' equityILS 150.3mILS 155.5mILS 159.6mILS 161.9mILS 164.3mILS 169.1mILS 156.8mILS 155.5m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.8%10.4%1.8%
Net income-2.1%9.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin23.6%24.7%25.6%28.0%
Operating margin-0.7%1.9%3.3%3.8%
Net margin-0.1%0.3%1.1%-0.4%

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings24.5-23.9-85.740.128.356.440.6-13.4-18.353.3
Price to sales0.50.50.61.01.11.11.41.70.90.7

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 6 Apr 2022.

FY2022FY2007FY2006
Paid in the year0.8680.300.60

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.